Myelofibrosis Drug Information

Guardant360® ctDNA liquid biopsy for treatment selection of patients with NSCLC

29 May 2020

Case presentation: The patient is a 46-year-old Korean lady who first presented with aggravating pleuritic chest pain characterised by a stabbing pain in the chest when inhaling and exhaling. A diagnosis of non-small cell lung cancer (NSCLC) was made from computed tomography (CT)-guided needle aspiration biopsy, and the tumour was found to be epidermal growth factor receptor (EGFR) mutation-positive (exon 19 deletion). Chest imaging revealed the presence of left-sided pleural seeding nodules. The patient was treated with afatanib with partial response as best response. Ten months after starting treatment, the patient experienced disease progression.

New advancements in MRI technology for improved diagnostics and patient experience

12 Feb 2019

At a recent Philips sponsored dinner symposium, a panel of industry and clinical experts convened to present data on key advancements in magnetic resonance imaging (MRI) solutions, with focus on two new Philips solutions – Ingenia Elition and Ingenia Ambition.

Denosumab: A critical aspect of metastatic prostate cancer treatment

Prof. Bertrand Tombal, Assoc Prof. Edmund Chiong, 18 May 2022

Men with metastatic prostate cancer (mPC) have an elevated risk of skeletal complications either due to bone metastases (skeletal-related events [SREs]), or from osteoporosis induced by androgen deprivation therapy (ADT). Two key opinion leaders recently shared their perspectives on bone complications in mPC as well as the use of bone-targeted agents (BTAs) such as denosumab (Xgeva) to reduce the risk of bone complications.

Professor Bertrand Tombal

Professor of Urology

Cliniques universitaires Saint-Luc & Université catholique de Louvain

Brussels, Belgium

Associate Professor Edmund Chiong

Head, Department of Urology

National University Hospital, Singapore